Deutsche Märkte öffnen in 6 Stunden 58 Minuten

Olema Pharmaceuticals, Inc. (OLMA)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
9,36-0,16 (-1,68%)
Börsenschluss: 04:00PM EDT
9,36 0,00 (0,00%)
Nachbörse: 04:20PM EDT

Olema Pharmaceuticals, Inc.

780 Brannan Street
San Francisco, CA 94103
United States
415-651-3316
https://olema.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter75

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Sean P. Bohen M.D., Ph.D.President, CEO & Director1,15MN/A1967
Mr. Shane William Charles Kovacs M.B.A.Chief Operating & Financial Officer820,37kN/A1974
Dr. Naseem Zojwalla M.D.Chief Medical Officer753,37kN/A1973
Mr. Geoffrey MogilnerVice President of Investor Relations & CommunicationsN/AN/AN/A
Ms. Julie DexterSenior VP & Head of PeopleN/AN/AN/A
Dr. David C. Myles Ph.D.Chief Discovery & Non-Clinical Development Officer200kN/A1963
Ms. Demiana Faltaos Ph.D., Pharm.D.VP & Head of Clinical PharmacologyN/AN/AN/A
Mr. John B. Moriarty Jr., J.D.Corporate Secretary434,32kN/A1968
Ms. Sasha Austin CPAVP of Finance & ControllerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Corporate Governance

Olema Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 6, Vorstand: 6, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.